EFM
SYRE icon

E Fund Management’s Spyre Therapeutics SYRE Stock Holding History

E Fund Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
5,184
-1,972
-28% -$144K 0.01% 292
2026
Q1 		$361K Buy
+7,156
New +$270K 0.01% 351

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

E Fund Management's SYRE Position: Q2 2026 in Review

E Fund Management reduced its Spyre Therapeutics (SYRE) stake by 28% in Q2 2026, selling an estimated $144K and leaving 5,184 shares worth $460K. The position accounts for 0.01% of the portfolio, ranked #292.

E Fund Management first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • E Fund Management held 5,184 shares of Spyre Therapeutics worth $460K as of Q2 2026.
  • E Fund Management sold 1,972 Spyre Therapeutics shares in Q2 2026, an estimated $144K.
  • Spyre Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #292 holding.
  • E Fund Management first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.